WellTheory, a virtual care platform for autoimmune disease, has raised $5 million in funding and launched proprietary AI tools to scale care delivery for the 50 million Americans with autoimmune conditions.
The funding round included new investors Samsung Ventures, Opal Ventures, and Up2 Fund, with continued support from existing investors Accel, OVO Fund, and Box Group. The capital will support WellTheory’s expansion into employer and health plan markets while accelerating development of its AI-powered care infrastructure.
“AI is no longer a nice-to-have in care delivery — it’s essential infrastructure,” said Ellen Rudolph, CEO and Co-founder of WellTheory. “This new round of funding is allowing us to double down on our AI strategy, streamline the most time-consuming parts of care, and expand into new markets.”
The company has launched two AI tools: Care Scribe and Care Hub. Care Scribe serves as an AI assistant that attends member sessions, transcribes conversations, and drafts follow-up notes and personalized care plans for provider review. According to the company, the tool has reduced provider preparation and documentation time by over 70%.
Care Hub acts as a unified command center for providers, aggregating member data, session history, and lab insights in one location. The platform includes dynamic workflows tailored to each session type and enables automated compliance tracking.
“Care delivery for folks with autoimmune disease is incredibly complex—our team built these tools to help give our Care Team time back for what matters most: supporting our members,” said Claire Rudolph, Co-Founder and Head of Product at WellTheory. “With WellTheory’s Care Hub and Care Scribe, we’re building the modern infrastructure autoimmune care has always needed.”
WellTheory’s platform provides whole-person care through an interdisciplinary team of autoimmune experts, including licensed registered dietitians and board-certified health coaches. The company describes its approach as addressing root causes rather than just managing symptoms.
Looking ahead, WellTheory plans to leverage its data ecosystem—including session transcripts, lab results, symptom tracking, and lifestyle inputs—to build what it calls a “next-generation intelligence layer” for personalized autoimmune care management.
The company aims to expand deeper automation in lab workflows and scheduling, enhanced analytics for providers, and an improved member-facing experience focused on personalization and long-term engagement.
